This study will assess the food-effect bioavailability of an extended release formulation of phenylephrine HCl and its bioequivalence to the marketed immediate release phenylephrine HCl product.

Inclusion Criteria:

• In good health
• Female participants must not be pregnant
• Agrees to use two acceptable methods of birth control throughout the study
• Agrees not to take monoamine oxidase inhibitor (MAOI) for 2 weeks prior to, during, and 2 weeks after the end of the study

Exclusion Criteria:

• Any significant medical condition which is a contraindication to the use of phenylephrine HCl, might interfere with the study, or requires treatment expected to affect blood pressure
• Any infectious disease within 4 weeks prior to initial treatment administration
• History of malignancy, except basal cell carcinoma
• Cannot comply with requirement to abstain from the use of any drugs (except acetaminophen or herbal/vitamin supplements) within 14 days prior to study and alcohol or xanthine-containing substances (coffee, chocolate) within 72 hours prior to study
• Received an investigational drug within thirty days prior to study drug dosing
• Known or apparent current or former drug addicts or alcoholics
• Positive for Human Immunodeficiency Virus (HIV) antibody, hepatitis B surface antigen, or hepatitis C antibody
• Cannot accept a high-fat, high-calorie breakfast
• Known allergy or intolerance to phenylephrine HCl
• Have used phenylephrine-containing product within 2 weeks prior to study start
• Have smoked tobacco, used tobacco products, or used a nicotine-containing smoking cessation aid within the past 6 months